A Milestone For PRP Safety

Claudia McGloin shares her views on the newly published JCCP guidance on PRP 

The recent guidance issued by the Joint Council for Cosmetic Practitioners (JCCP) on Platelet-Rich Plasma (PRP) procedures represents an important and timely milestone for patient safety and professional accountability within regenerative medicine.

Having been involved in the working group that contributed to the development of this guidance, I welcomed the opportunity to support a framework that reflects both the enormous potential of PRP and the responsibilities that come with its delivery. As regenerative treatments continue to grow in popularity, it is essential that patient safety remains at the forefront of clinical practice.

PRP has become one of the most widely used regenerative treatments in medical aesthetics. Its appeal lies in its autologous nature and its potential to support tissue repair and regeneration. However, despite its increasing use, there remains significant variation in how treatments are prepared, delivered and governed. Differences in devices, protocols, practitioner training and clinical oversight can all influence both treatment outcomes and patient safety.

The JCCP guidance addresses these concerns directly. Importantly, it reinforces that PRP is not simply a cosmetic treatment. It is a medical procedure involving blood collection, processing and reinjection. As such, it requires appropriate clinical knowledge, robust patient assessment, informed consent, infection prevention measures and the ability to recognise and manage complications should they arise.

One of the most significant aspects of the guidance is its emphasis on the use of MHRA registered medical devices, including centrifuges and blood collection systems specifically designed for autologous PRP procedures. This is a crucial step towards improving consistency, quality assurance and public confidence. As clinicians, we have a responsibility not only to understand the treatment itself, but also the devices, processes and regulatory requirements that underpin safe practice.

Recent MHRA related regulatory discussions and subsequent professional guidance have also highlighted the complex legal and governance considerations surrounding the manufacture, supply and administration of PRP. These discussions reinforce the need for appropriately trained and regulated healthcare professionals to deliver treatments within robust clinical governance frameworks. This is not about limiting access to innovation, it is about ensuring that innovation is delivered safely, ethically and in the best interests of patients.

The guidance further highlights the importance of compliance with the Blood Safety and Quality Regulations 2005. This is particularly relevant given recent concerns regarding infection prevention standards and the handling of blood products within some settings. Patients have the right to expect that procedures involving blood collection and processing are performed to the same high standards that would be expected elsewhere in healthcare.

I am particularly pleased to see recognition that PRP for hair restoration constitutes a medical procedure. This provides much needed clarity for practitioners, regulators and enforcement agencies alike. It also acknowledges the reality that procedures involving blood collection and reinjection require appropriate clinical oversight, regardless of the indication being treated.

Importantly, this guidance should not be viewed as a barrier to the advancement of PRP. On the contrary, it provides a foundation for the safe, ethical and evidence based growth of regenerative medicine. Responsible practitioners have nothing to fear from higher standards, such standards help protect patients, practitioners and the long-term credibility of the specialty.

Patient safety should never be an afterthought. It must remain the foundation upon which the future of regenerative medicine is built. The JCCP guidance represents an important first step towards greater consistency, accountability and public protection. As further standards are developed by the Cosmetic Practice Standards Authority, I hope we will continue to see meaningful collaboration between regulators, professional bodies and clinicians to ensure that regenerative medicine evolves safely, responsibly and with patient welfare at its core.